PAVING THE WAY FOR AN ALS TREATMENT
By digging deeper into the cause of amyotrophic lateral sclerosis (ALS), and investigating its various pathologies, we are developing precision medications to effectively treat ALS and frontotemporal dementia.
ALS PATIENTS
ALS has a devastating impact on patients and families. Through DNA analysis and clinical studies, we now know that there are several distinct ALS pathologies that must be treated individually to achieve success. Through our work with ALS patient-derived stem cells, our close collaborators in the clinic and the worldwide ALS research community, we have identified the disease cause for three distinct ALS pathologies – motor system hyperactivity, toxic protein aggregates, and cellular waste clearance.
For ALS patients in the Tri-state area, please visit the website of the MAC Angels for more information and support: https://www.macangels.org/
OUR MISSION
ALS can affect anyone and with no meaningful treatment options, the predicted life expectancy following diagnosis is roughly 3 years. Our mission at QurAlis is to use the latest advances in drug design and precision medicine to develop clinically meaningful treatments for ALS that will provide much-needed hope to patients that we can eventually conquer this disease.
MESSAGES OF HOPE
We can defeat ALS. We have brought world class ALS researchers, doctors and industry experts together to make the right therapies for the right ALS patients and we will not stop until we have succeeded in our mission.
Kasper Roet
Chief Executive Officer
I was introduced only relatively recently to the challenge of ALS and its devastating course in patients. The need for effective treatment is so great that I have become quite obsessed with contributing, both by exploring ALS disease mechanisms in my academic lab and as cofounder of QurAlis, and will not rest until we have made a meaningful impact in halting or preventing the disease.
Clifford J. Woolf
Founder
For the first time in history we have genuine reason to believe we can treat patients with some forms of ALS in the years to come.
Jonathan J. Fleming
Executive Chair
We have known so little in the past about why motor neurons degenerate in ALS that it has been difficult to generate candidate therapeutics with the precision required for them to become actual cures. The transformative genetic and stem cell technologies being employed at QurAlis will allow us to test candidate therapeutics on motor neurons derived from patients during their development, greatly increasing our likelihood of eventual successful in later clinical trials.